Compare LAC & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAC | HROW |
|---|---|---|
| Founded | 2023 | 1998 |
| Country | Canada | United States |
| Employees | N/A | 373 |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2023 | N/A |
| Metric | LAC | HROW |
|---|---|---|
| Price | $4.31 | $42.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $6.14 | ★ $69.86 |
| AVG Volume (30 Days) | ★ 11.7M | 761.6K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $31.62 |
| Revenue Next Year | N/A | $50.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.47 | $28.54 |
| 52 Week High | $10.52 | $54.98 |
| Indicator | LAC | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 39.96 | 71.96 |
| Support Level | $3.66 | $40.61 |
| Resistance Level | $5.40 | $51.01 |
| Average True Range (ATR) | 0.29 | 2.15 |
| MACD | -0.05 | 1.11 |
| Stochastic Oscillator | 8.71 | 87.63 |
Lithium Americas Corp is a Canadian-based resource and materials company focused on developing, building and operating lithium deposits and chemical processing facilities. The company also holds investments in Green Technology Metals Limited (GT1) and Ascend Elements, Inc. (Ascend Elements), and exploration properties in the U.S. and Canada. The company's flagship asset is Thacker Pass, a sedimentary-based lithium deposit located in the McDermitt Caldera in Humboldt County, in northern Nevada (Thacker Pass or the Project). The company operates in only one operating segment and one geographical segment.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.